Broker Morgans has reviewed three prominent ASX-listed companies this week, responding to trading updates and results across the travel, healthcare, and banking sectors. The Morgans Flight Centre rating, Sigma Healthcare share outlook, and Westpac shares broker update each carry distinct implications for investors tracking these names.
Figure 1: JPMorgan branding representing global investment banking and financial market activity [Courtesy: Financial Express]
The reviews reflect a week of significant corporate newsflow, with Middle East conflict disruption, pharmaceutical tailwinds, and banking margin compression all shaping the broker’s revised positions.
Morgans Retains Buy on Flight Centre Despite Leisure Headwinds
Flight Centre Travel Group Ltd (ASX: FLT) surprised Morgans by reaffirming its FY26 earnings guidance despite ongoing disruption from the Middle East conflict. The Morgans Flight Centre rating remains a Buy, though the broker has trimmed its price target to A$14.55 per share.
Morgans noted that the conflict is creating near-term uncertainty and temporarily disrupting international travel patterns. The leisure segment has been the most affected, with April profit running approximately A$10 million below the prior corresponding period.
Guidance Held, But FY27 Concerns Linger
Despite the guidance reaffirmation, Morgans expressed concern that Flight Centre may need to revise its outlook after the key May to June trading period.
The broker said: “While the reiteration of guidance was better than feared, our concern is that following its key trading period (May-June), FLT will likely need to revise guidance as we expect leisure demand will remain weak.”
Morgans made material revisions to its forecasts and now sits well below the Company’s own guidance range.
However, it maintained a constructive long-term view, noting that the first nine months of FY26 were strong before the conflict intensified. The broker added: “We are buyers of FLT post the earnings downgrade, given the company is worth materially more than the current share price.”
Sigma Healthcare Downgraded to Accumulate After Share Price Rally
The Sigma Healthcare share outlook has shifted modestly following a solid trading update from Sigma Healthcare Ltd (ASX: SIG), the Company behind Chemist Warehouse.
Morgans was pleased with the update but moved its rating from Buy to Accumulate, citing recent share price strength compressing total return potential. The revised price target stands at A$3.30 per share, trimmed from A$3.36.
Figure 2: Sigma Healthcare distribution and operations facility [Courtesy: ETB2Bimg]
Sigma’s update covered domestic trading to 30 Apr 2026 and international trading to 31 Mar 2026. The Company flagged continuing tailwinds from GLP-1 pharmaceutical demand, ongoing expansion into the United Kingdom, and growing distribution capacity in New Zealand.
Minor Forecast Upgrades, Valuation Nudged Lower
Morgans made minor upgrades to its Sigma Healthcare forecasts following the update. However, a higher risk-free rate saw the broker’s valuation reduce modestly. The broker stated: “Recent share price strength sees us move to an ACCUMULATE (from BUY) recommendation.”
For investors monitoring the Sigma Healthcare share outlook, the Accumulate rating signals that the broker still sees upside from current levels, though not enough to warrant a full Buy conviction at this stage of the share price run.
Westpac Upgraded to Trim as Morgans Moderates Its Sell Call
The Westpac shares broker update from Morgans reflects a partial softening of its previously bearish stance. Following Westpac Banking Corp’s latest results, Morgans has lifted its recommendation from Sell to Trim, with a revised price target of A$33.07 per share, down approximately 3% from its prior target.
Figure 3: Westpac corporate branding [Courtesy: Fintel]
Morgans acknowledged strong volume momentum at the bank but noted that earnings leverage has dissipated. Margin compression and rising credit risk pressures have weighed on the results.
The broker downgraded its FY27 and FY28 earnings per share and dividend per share estimates by 4 to 5%, driven by revenue approximately 2% lower and costs approximately 1% higher than previously modelled.
Total Return Potential Remains Negative at Current Prices
Despite the upgrade from Sell to Trim, the Westpac shares broker update carries a cautious tone. Morgans said: “We moderate from SELL to TRIM, given potential TSR of c.-8% at current prices.” The revised price target of A$33.07 still implies meaningful downside from current trading levels, with only a modest dividend yield as a partial offset.
For investors tracking this Westpac shares broker update, the Trim rating signals that Morgans sees the risk-reward as unfavourable at present, though not as acutely negative as the prior Sell position suggested.
Industry Outlook
Australian equitie are navigating a complex mid-year environment in 2026. Geopolitical disruption is reshaping travel demand patterns, GLP-1 pharmaceutical growth is emerging as a structural tailwind for healthcare distributors, and the major banks are facing a tightening squeeze between volume growth and margin compression.
Morgans’ ratings across Flight Centre, Sigma Healthcare, and Westpac reflect these broader sector dynamics, with each Company responding differently to the same macro backdrop.
Future Direction and Impact on ASX Investors
The three Morgans ratings updates carry direct read-throughs for investors holding or considering these names:
- The Morgans Flight Centre rating remains a Buy at A$14.55 per share, with the broker expecting leisure demand to recover after a conflict-driven downturn, consistent with historical travel rebound patterns
- Flight Centre’s May to June trading period will be the critical window for whether FY26 guidance can be sustained or must be revised
- The Sigma Healthcare share outlook has shifted to Accumulate at A$3.30, reflecting solid fundamentals but limited additional upside at current price levels following recent strength
- Sigma’s GLP-1 tailwind, UK market entry, and New Zealand distribution expansion remain medium-term growth drivers worth monitoring
- The Westpac shares broker update points to approximately 8% total return downside at current prices, with FY27 and FY28 earnings estimates cut 4 to 5%
- Morgans’ move from Sell to Trim on Westpac reflects a marginal improvement in risk-reward, not a change in the fundamental concern around margin and credit quality
ALSO READ: How Beginner Investors Can Start on the Australian Stock Market in 2026
Frequently Asked Questions
Q1. What is Morgan’s Flight Centre rating as of May 2026?
Ans. Morgans has retained a Buy rating on Flight Centre with a reduced price target of A$14.55 per share, despite material forecast revisions linked to Middle East conflict disruption.
Q2. Why has Morgan downgraded Sigma Healthcare?
Ans. Recent share price strength has compressed total return potential. Morgans moved from Buy to Accumulate with a trimmed price target of A$3.30, reflecting solid fundamentals but reduced upside at current levels.
Q3. What is Morgan’s current view on Westpac shares?
Ans. Morgans has upgraded Westpac from Sell to Trim with a price target of A$33.07 per share. The broker still sees approximately 8% total return downside at current prices.
Q4. What is driving Sigma Healthcare’s positive trading update?
Ans. Continuing GLP-1 pharmaceutical tailwinds, expansion into the UK market, and growing distribution capacity in New Zealand were the key highlights from Sigma’s trading update.
Q5. When is the next key event for Flight Centre investors?
Ans. The May to June trading period is the critical window. Morgans expects this will determine whether Flight Centre can sustain its FY26 guidance or will need to revise it downward.
Disclaimer
This article is intended for informational purposes only and does not constitute financial or investment advice. All content is based on publicly available broker commentary and reporting published online. Share price and market data reflect figures available at the time of publication. Investing in securities involves risk. Readers should conduct their own research and seek independent financial advice before making any investment decisions. Colitco does not hold any position in the companies or organisations mentioned.
Sources
- https://www.fool.com.au/2026/05/07/what-is-morgans-saying-about-flight-centre-sigma-and-westpac-shares
- https://www.asx.com.au/markets/company/FLT
- https://www.asx.com.au/markets/company/SIG
- https://www.asx.com.au/markets/company/WBC
Last modified: May 8, 2026
